Associate Professor David Elliott leads the Heart Disease group at the Murdoch Children's Research Institute (MCRI) and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Associate Professor Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Associate Professor Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.
Associate Professor David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Associate Professor Elliott began using human pluripotent stem cells in a second post-doc with Professors Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Associate Professor David Elliott leads the Heart Disease group at the Murdoch Children's Research Institute (MCRI) and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Associate...
Associate Professor David Elliott leads the Heart Disease group at the Murdoch Children's Research Institute (MCRI) and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Associate Professor Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Associate Professor Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.
Associate Professor David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Associate Professor Elliott began using human pluripotent stem cells in a second post-doc with Professors Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Top Publications
Birket, MJ, Casini, S, Kosmidis, G, Elliott, DA, Gerencser, AA, Baartscheer, A, Schumacher, C, Mastroberardino, PG, Elefanty, AG, Stanley, EG, et al.
PGC-1α and reactive oxygen species regulate human embryonic stem cell-derived cardiomyocyte function..
Stem Cell Reports
1(6)
:
560 -574
2013
view publication
Raynaud, CM, Halabi, N, Elliott, DA, Pasquier, J, Elefanty, AG, Stanley, EG, Rafii, A.
Human embryonic stem cell derived mesenchymal progenitors express cardiac markers but do not form contractile cardiomyocytes..
PLoS One
8(1)
:
e54524
2013
view publication
Mummery, CL, Zhang, J, Ng, ES, Elliott, DA, Elefanty, AG, Kamp, TJ.
Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview..
Circ Res
111(3)
:
344 -358
2012
view publication
Koss, M, Bolze, A, Brendolan, A, Saggese, M, Capellini, TD, Bojilova, E, Boisson, B, Prall, OWJ, Elliott, DA, Solloway, M, et al.
Congenital asplenia in mice and humans with mutations in a Pbx/Nkx2-5/p15 module..
Dev Cell
22(5)
:
913 -926
2012
view publication
Micallef, SJ, Li, X, Schiesser, JV, Hirst, CE, Yu, QC, Lim, SM, Nostro, MC, Elliott, DA, Sarangi, F, Harrison, LC, et al.
INS(GFP/w) human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cells..
Diabetologia
55(3)
:
694 -706
2012
view publication